• Explore /
  • Poster
  • / Comparative effectiveness of first-line (1L) ipilimumab plus nivolumab (Ipi + Nivo) versus immune checkpoint inhibitors + tyrosine kinase inhibitors (ICI + TKI) in patients (pts) with intermediate or poor (I/P) risk metastatic clear cell renal cell carcinoma (mccRCC).

Comparative effectiveness of first-line (1L) ipilimumab plus nivolumab (Ipi + Nivo) versus immune checkpoint inhibitors + tyrosine kinase inhibitors (ICI + TKI) in patients (pts) with intermediate or poor (I/P) risk metastatic clear cell renal cell carcinoma (mccRCC).

Abstract Poster

Authors

null

Micah Ostrowski

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

Micah Ostrowski , Yeonjung Jo , Georges Gebrael , Chadi Hage Chehade , Arshit Narang , Gliceida Galarza Fortuna , Vinay Mathew Thomas , Beverly Chigarira , Ethan Anderson , Archisman Mazumder , Zeynep Irem Ozay , Neeraj Agarwal , Benjamin L. Maughan , Umang Swami

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4557)

DOI

10.1200/JCO.2024.42.16_suppl.4557

Abstract #

4557

Poster Bd #

252

Abstract Disclosures

Similar Posters

First Author: Joseph Vento

First Author: Vishal Navani

First Author: Pratik Rane

First Author: Bradley Alexander McGregor